- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT06433921
Une étude pour comparer la puissance relative du salbutamol administré via des inhalateurs-doseurs (MDI) contenant des propulseurs HFA-152a au HFA-134a chez des asthmatiques légers âgés de 18 à 65 ans inclus
Une étude de phase 1, randomisée, en 2 parties, croisée à 7 voies (partie 1) et croisée à 7 voies (partie 2), avec dispositif actif en aveugle, étude à dose unique chez des asthmatiques légers âgés de 18 à 65 ans pour évaluer le parent Puissance du salbutamol administré via des inhalateurs-doseurs contenant les propulseurs HFA-152a (test) et HFA-134a (référence) via une bronchoprovocation à la méthacholine et des effets pharmacodynamiques systémiques
The primary objectives of the study are: Part 1: to characterize the potency and variability of dose response on efficacy (Provocative concentration of methacholine causing at least a 20% fall in forced expiratory volume (FEV1) [PC20]) of salbutamol administered via MDI with salbutamol HFA-134a or salbutamol HFA-152a in participants with mild asthma. Part 2: to compare the comparative dose response on efficacy (PC20) of salbutamol when administered via MDI with salbutamol HFA-134a or salbutamol HFA-152a in participants with mild asthma.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Type d'étude
Inscription (Estimé)
Phase
- La phase 1
Contacts et emplacements
Coordonnées de l'étude
- Nom: US GSK Clinical Trials Call Center
- Numéro de téléphone: 877-379-3718
- E-mail: GSKClinicalSupportHD@gsk.com
Sauvegarde des contacts de l'étude
- Nom: EU GSK Clinical Trials Call Center
- Numéro de téléphone: +44 (0) 20 89904466
- E-mail: GSKClinicalSupportHD@gsk.com
Lieux d'étude
-
-
Greater Manchester
-
Manchester, Greater Manchester, Royaume-Uni, M23 9QZ
- Recrutement
- GSK Investigational Site
-
Chercheur principal:
- Dave Singh
-
Contact:
- US GSK Clinical Trials Call Center
- Numéro de téléphone: 877-379-3718
- E-mail: GSKClinicalSupportHD@gsk.com
-
Contact:
- EU GSK Clinical Trials Call Centre
- Numéro de téléphone: +44 (0) 20 8990 4466
- E-mail: GSKClinicalSupportHD@gsk.com
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Male or female; females may be of childbearing potential, of nonchildbearing potential, or postmenopausal.
- Participant must be 18 to 65 years of age inclusive, at the time of screening.
- ≥50 kg, at the time of screening.
- Body mass index (BMI) with 19.0-35.0 kg/m2 inclusive, at the time of screening.
4. Documented history of asthma ≥ 6 months. 5. Receiving 1 of following asthma treatments, at a stable dose, for at least 12 weeks prior to the screening visit and is anticipated to remain stable for the duration of the study: i. Short-acting beta-agonist (SABA) only. ii. Daily maintenance low-dose inhaled corticosteroids (ICS) (defined as 100-250 μg/day fluticasone propionate or equivalent plus or minus SABA which is anticipated to remain stable for the duration of the study.
iii. Daily maintenance low-dose ICS + Long-acting beta-2 agonist (LABA) therapy (low-dose ICS defined as 100-250 μg/day fluticasone propionate or equivalent as defined by GINA [GINA, 2023]) plus or minus SABA, which is anticipated to remain stable for the duration of the study.
6. No severe asthma exacerbations within 6 months prior to screening and ≤1 severe exacerbation during the 12 months prior to screening.
7. Pre-bronchodilator FEV1 ≥80% of predicted, at screening. 8. PC20 to methacholine of ≤8 mg/mL, at screening. 9. Participants should be able to withhold SABA for ≥12 hours and LABA-containing medications for ≥48 hours for the purposes of performing the spirometry and methacholine challenge at screening and during the study visits (treatment periods).
10. A female participant is eligible to participate if she is not pregnant or breastfeeding, and Is a woman of woman of nonchildbearing potential (WONCBP) OR ii. Is a woman of child bearing potential (WOCBP) and using a contraceptive method that is highly effective.
11. Provide signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form and in this protocol.
12. Non-smokers who have not used any tobacco containing-products within 12 months prior to study start, and with a total pack year history of ≤10 pack years.
Exclusion Criteria:
-
Medical Conditions
- A history of life-threatening asthma or asthma that is unstable in the opinion of the investigator.
- A history of respiratory diseases to include (but not limited to): pneumothorax, pulmonary fibrotic disease, bronchopulmonary dysplasia, chronic bronchitis, cystic fibrosis, bronchiectasis, interstitial lung disease, emphysema, chronic obstructive pulmonary disease, tuberculosis, or other respiratory abnormalities other than asthma.
- Asymptomatic gallstones.
- History or current evidence of hematologic, neurologic, psychiatric, or other diseases that, in the opinion of the investigator, would put the participant at risk through study participation, or would affect the study analyses if the disease exacerbates during the study.
- Recent eye surgery or any other condition in which raised intracranial pressure (caused by forceful exhalation) would be harmful.
- Current use of cholinesterase inhibitor medication e.g., to treat myasthenia gravis.
-
Exposure to more than 4 new chemical entities within 12 months prior to the first dosing day or participation in a clinical study within 30 days of study start, or 5 half-lives of study drug if that is longer.
-
Participants who are currently or in the last 15 days have worked nightshifts.
-
Regular alcohol consumption within 6 months prior to the study defined as: an average weekly intake of >21 units for males or >14 units for females.
-
A positive test result for drugs of abuse (including tetrahydrocannabinol) at screening or Day -1.
-
Use of combustible tobacco products, and non-combustible nicotine delivery systems, inclusive of cigarettes, cigars, pipes, and materials used to "vape" within 12 months prior to the start of the study.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Autre
- Répartition: Randomisé
- Modèle interventionnel: Affectation croisée
- Masquage: Tripler
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Part 1
Part 1 will consist of a 7 treatment, 7 period cross-over evaluation with all participants receiving the following treatments once, randomized to varying pre-specified sequences of:
A minimum of a 2-day and maximum of a 7-day methacholine washout will separate each treatment period. |
A single 100, 200 or 400 μg dose, given as 1, 2 or 4 × 100 μg actuations (exvalve) at 20 second intervals. A single 100, 200 or 400 μg dose, given as 1, 2 or 4 × 100 μg actuations (exvalve) at 20 second intervals. A single placebo HFA-152a suspension or placebo HFA-134a suspension dose, given as at 20 second intervals. |
|
Expérimental: Part 2
Part 2 will consist of a 7 treatment, 7-way cross-over with all participants receiving the following treatments given once, randomized to varying pre-specified sequences of:
A minimum of a 3-day and maximum of a 7-day methacholine washout will separate each treatment period. |
A single 100, 200 or 400 μg dose, given as 1, 2 or 4 × 100 μg actuations (exvalve) at 20 second intervals. A single 100, 200 or 400 μg dose, given as 1, 2 or 4 × 100 μg actuations (exvalve) at 20 second intervals. A single placebo HFA-152a suspension or placebo HFA-134a suspension dose, given as at 20 second intervals. |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Délai |
|---|---|
|
Part 1 & Part 2: Provocative concentration of methacholine causing at least a 20% fall in FEV1 (PC20)
Délai: Up to 11 weeks
|
Up to 11 weeks
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Part 1 & Part 2: Peak QTc Interval
Délai: Up to 11 weeks
|
Up to 11 weeks
|
|
|
Part 1 & Part 2: Peak Heart Rate (HR)
Délai: Up to 11 weeks
|
Up to 11 weeks
|
|
|
Part 1 & Part 2: Minimum Serum Potassium
Délai: Up to 11 weeks
|
Up to 11 weeks
|
|
|
Part 1: Maximum Observed Plasma Concentration (Cmax)
Délai: Up to 11 weeks
|
Up to 11 weeks
|
|
|
Part 1: Time to Reach Cmax (Tmax)
Délai: Up to 11 weeks
|
Up to 11 weeks
|
|
|
Part 1: Area Under the Plasma Concentration-time Curve up to Last Time With Concentrations Above the Lower Limit of Quantification (LLOQ) (AUC[0-last])
Délai: Up to 11 weeks
|
Up to 11 weeks
|
|
|
Part 1 & Part 2: Incidence of Adverse Events (AEs) and Serious Adverse Events (SAEs)
Délai: Up to 11 weeks
|
Up to 11 weeks
|
|
|
Part 1 & Part 2: Absolute Values for 12-lead Electrocardiogram (ECG) Recording of HR
Délai: Up to 11 weeks
|
Up to 11 weeks
|
|
|
Part 1 & Part 2: Number of Participants with Clinically Significant Changes in Clinical Laboratory Parameters
Délai: Up to 11 weeks
|
Up to 11 weeks
|
|
|
Part 1 & Part 2: Absolute Values of Vital Signs (Systolic and Diastolic Blood Pressure)
Délai: Up to 11 weeks
|
Up to 11 weeks
|
|
|
Part 1 & Part 2: Absolute Values of Vital Signs (Pulse Rate)
Délai: Up to 11 weeks
|
Up to 11 weeks
|
|
|
Part 1 & Part 2: Absolute Values for 12-lead ECGs Recording of Intervals
Délai: Up to 11 weeks
|
Intervals recorded: - PR. - QRS. - QT. - QTc |
Up to 11 weeks
|
|
Part 1 & Part 2: Change from Baseline for Post-dose 12-lead ECGs Recording of HR
Délai: Baseline and up to 11 weeks
|
The 3 predose measures will be recorded and will be averaged for HR to derive 1 baseline value. |
Baseline and up to 11 weeks
|
|
Part 1 & Part 2: Change from Baseline for Post-dose 12-lead ECGs Recording of Intervals
Délai: Up to 11 weeks
|
The 3 predose measures will be recorded and will be averaged for QTc interval to derive 1 baseline value. Intervals recorded: - PR. - QRS. - QT. - QTc |
Up to 11 weeks
|
Collaborateurs et enquêteurs
Parrainer
Publications et liens utiles
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- 219729
- 2024-511220-14 (Numéro EudraCT)
- 2024-511220-14-00 (Ctis: EudraCT (EU))
- 2024-511220-14-00 (Identificateur de registre: CTIS (EU))
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Description du régime IPD
Qualified researchers may request access to anonymized individual patient-level data (IPD) and related study documents of the eligible studies via the Data Sharing Portal. Details on GSK's data sharing criteria can be found at: https://www.gsk.com/en-gb/innovation/trials/data-transparency/
Délai de partage IPD
Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or terminated asset(s) across all indications.
Critères d'accès au partage IPD
Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension may be granted, when justified, for up to 6 months.
Type d'informations de prise en charge du partage d'IPD
- PROTOCOLE D'ÉTUDE
- SÈVE
- CIF
- RSE
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .